Breast Cancer
Conditions
Keywords
ductal breast carcinoma in situ
Brief summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in tissue samples from patients with ductal breast carcinoma in situ.
Detailed description
OBJECTIVES: * To validate the prognostic utility of a new ductal breast carcinoma in situ (DCIS) genomic score and the Oncotype DX Recurrence Score® assay in tissue samples from patients with DCIS enrolled on clinical trial ECOG-E5194. OUTLINE: RNA extracted from archived tissue samples are analyzed for gene expression profile by Oncotype DX Recurrence Score® assay (a reverse transcriptase-PCR-based assay).
Interventions
GENETICRNA analysis
GENETICgene expression analysis
GENETICreverse transcriptase-polymerase chain reaction
OTHERlaboratory biomarker analysis
Sponsors
National Cancer Institute (NCI)
ECOG-ACRIN Cancer Research Group
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of ductal breast carcinoma in situ * Enrolled on clinical trial ECOG-E5194 * Local surgery without radiotherapy * Treated or not treated with tamoxifen * Available tissue samples * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ipsilateral local failure (first event of invasive or DCIS recurrence) | 1 month |
Secondary
| Measure | Time frame |
|---|---|
| Contralateral breast cancer (invasive or DCIS) | 1 month |
Outcome results
None listed